In advanced NSCLC, the first line treatment with anti‐PD‐(L)1 agents is recommended in patients with ≥50% PD‐L1 tumor proportion score (TPS) and in combination with chemotherapy with lower PD‐L1 scores.7, 15, 16, 17. Here, CD274 is linked to neoplasm.